The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial

Dickon Hayne discusses the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.

Image courtesy of interviewee. May 29, 2024

Log-in or Sign-up to Faculti
Currently viewing this subject insight as a guest. You have insight(s) remaining for this month.

Leave a Reply

Your email address will not be published.

Copyright © Faculti Media Limited 2013 - 2024. All rights reserved.
error: